NASDAQ:ALPN
Alpine Immune Sciences Inc Stock News
$64.56
-0.0600 (-0.0929%)
At Close: Apr 26, 2024
Strength Seen in Alpine Immune Sciences, Inc. (ALPN): Can Its 7.5% Jump Turn into More Strength?
06:01am, Friday, 04'th Nov 2022
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in t
After Plunging 23.2% in 4 Weeks, Here's Why the Trend Might Reverse for Alpine Immune Sciences, Inc. (ALPN)
01:35pm, Friday, 28'th Oct 2022 Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street a
After Plunging 23.2% in 4 Weeks, Here's Why the Trend Might Reverse for Alpine Immune Sciences, Inc. (ALPN)
11:18am, Friday, 28'th Oct 2022
Alpine Immune Sciences, Inc. (ALPN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street a
Alpine Immune Sciences: ALPN-202 May Be Dead, But The Company Isn't
10:33am, Thursday, 27'th Oct 2022
The recent termination of ALPN-202 trials due to another patient's death caused the share price to plummet. While this was anticipated, I believe that the market has overreacted due to several reasons
Alpine: Ramifications Of The Davoceticept Termination
05:51am, Thursday, 27'th Oct 2022
The second patient death prompted Alpine to terminate any future development of davoceticept. It's prudent that Alpine stopped unfruitful developments early on to focus on lower-hanging fruits.
What Happened This Week: Poor Earnings Reports And Buybacks
08:23pm, Friday, 21'st Oct 2022 Investing.com
Esperion Therapeutics (ESPR) Moves 6.5% Higher: Will This Strength Last?
12:22pm, Wednesday, 12'th Oct 2022 Zacks Investment Research
Esperion Therapeutics (ESPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric
US Stock Futures Edge Higher; All Eyes On Fed Decision
09:12am, Wednesday, 21'st Sep 2022 Benzinga
Pre-open movers
U.S. stock futures traded slightly higher in early pre-market trade on Wednesday after recording losses on Tuesday. The Dow Jones closed lower by more than 300 points, while the Nasdaq
General Mills, Lennar And 3 Stocks To Watch Heading Into Wednesday
08:23am, Wednesday, 21'st Sep 2022 Benzinga
With US stock futures trading slightly lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
Wall Street expects General Mills, Inc. (NYSE: GIS) to r
Alpine Immune Sciences, Inc. (ALPN) Moves to Buy: Rationale Behind the Upgrade
04:00pm, Monday, 15'th Aug 2022 Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Alpine Immune Sciences, Inc. (ALPN) Moves to Buy: Rationale Behind the Upgrade
01:32pm, Monday, 15'th Aug 2022
Alpine Immune Sciences, Inc. (ALPN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stevanato Group (STVN) Q2 Earnings and Revenues Beat Estimates
11:55am, Thursday, 04'th Aug 2022 Zacks Investment Research
Stevanato (STVN) delivered earnings and revenue surprises of 8.33% and 5.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines, Inc. (RVMD) Surges 5.6%: Is This an Indication of Further Gains?
01:42pm, Friday, 24'th Jun 2022 Zacks Investment Research
Revolution Medicines, Inc. (RVMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in
Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Tops Revenue Estimates
09:55pm, Thursday, 12'th May 2022 Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -47.06% and 2.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the
Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Tops Revenue Estimates
07:34pm, Thursday, 12'th May 2022
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -47.06% and 2.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the
